Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

11.900
+0.6205.50%
Volume:6.19M
Turnover:73.17M
Market Cap:11.80B
PE:-36.17
High:11.980
Open:11.280
Low:11.280
Close:11.280
52wk High:18.750
52wk Low:1.480
Shares:992.00M
HK Float Shares:992.00M
Volume Ratio:0.97
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.329
ROE:-12.77%
ROA:-12.32%
PB:5.77
PE(LYR):-36.17
PS:4560.50

Loading ...

ASCLETIS-B (01672) Rises Over 4% Again as ASC36 and ASC35 Combo Advances to Clinical Development

Stock News
·
Yesterday

ASCLETIS-B (01672): Monthly-Dose Next-Gen Amylin Receptor Agonist ASC36 and GLP-1R/GIPR Dual-Target Agonist ASC35 Combo Advances to Clinical Development

Stock News
·
Yesterday

Ascletis Pharma Inc. (1672) Announces Once-Monthly Co-Formulation of ASC36 and ASC35 for Obesity Treatment

Bulletin Express
·
Yesterday

Ascletis Pharma (SEHK:1672): Evaluating Valuation After Promising Phase Ib Obesity Data and Pipeline Expansion

Simply Wall St.
·
Nov 12

HK Movers | Innovative Drug Stocks Jump With Ascletis Pharma and BeOne Medicines up 6%

Tiger Newspress
·
Nov 12

HK Stock Movement | ASCLETIS-B (01672) Surges Over 7% in Late Trading as ASC36 Enters Clinical Development Phase, IND Application to Be Submitted in Q2 Next Year

Stock News
·
Nov 11

Ascletis Pharma (SEHK:1672) Is Up 5.5% After Revealing Promising Obesity Drug Updates at ObesityWeek 2025 Has The Bull Case Changed?

Simply Wall St.
·
Nov 11

HK Movers | Biomedical Stocks Jump With Ascletis Pharma up 9%

Tiger Newspress
·
Nov 10

MSCI Global Small Cap Index Rebalance: Ascletis-B (01672), Chabaidao (02555) Among 22 Stocks Added

Stock News
·
Nov 06

Hong Kong Stock Buyback Summary | November 6

Stock News
·
Nov 06

ASCLETIS-B (01672) Repurchased 100,000 Shares for HK$924,000 on November 5

Stock News
·
Nov 05

Ascletis Pharma Files HKEX Disclosure on Repurchase of 100,000 Shares for HKD 923,960

Reuters
·
Nov 05

Ascletis Pharma (1672) Announces Positive Phase Ib Results for ASC30 and Promising Preclinical Findings on ASC31–ASC47 Combination

Bulletin Express
·
Nov 05

ASCLETIS-B (01672) Presents Full Analysis of ASC30 Oral Tablet Ib Study, ASC30 Injection Ib Study, and ASC31/ASC47 Combination Preclinical Research at ObesityWeek® 2025

Stock News
·
Nov 05

Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment

Reuters
·
Nov 05

Ascletis Pharma Inc. (01672) Announces Monthly Return for 31 October 2025

Bulletin Express
·
Nov 04

Hong Kong Stock Buyback Summary | November 3

Stock News
·
Nov 03

Assessing Ascletis Pharma (SEHK:1672) Valuation Following ASC36 Obesity Pipeline Advancement

Simply Wall St.
·
Nov 03

Ascletis Pharma (SEHK:1672) Advances AI-Discovered Obesity Drug ASC36 Is Innovation Accelerating Competitive Positioning?

Simply Wall St.
·
Nov 01

Ascletis Pharma (01672) Announces Share Repurchase and Updated Share Figures

Bulletin Express
·
Oct 31